- Centers for Disease Control and Prevention
- 3/2021
- Standardized Collection of Standardized Clinical Data
- Linking of Clinical and Other Data for Research
- Use of Clinical Data for Research
STATUS: Active Project
BACKGROUND
This project builds on an existing PCORTF project funded to establish a maternal and infant network to examine practice patterns and outcomes associated with the treatment for Opioid Use Disorder (OUD) during pregnancy, called MAT-LINK. This network created a data platform and standard maternal and infant data elements to collect linked maternal and infant data among women treated for OUD during pregnancy in four clinical sites across the US: Boston Medical Center, Ohio State University, University of Utah, and Kaiser Foundation Research Institute Northwest in Oregon and Washington.
To strengthen the robustness and representativeness of future findings, MAT-LINK 2 will add 2-3 additional clinical entities to increase the study population of women with varied racial, ethnic, and socioeconomic characteristics and expand the geographic reach. In addition, the period of collection of outcome data for infants will be expanded up to age six years. This will allow for a more comprehensive assessment of cognitive and motor developmental delays that may not be apparent in younger children.
MAT-LINK 2 will strengthen the existing surveillance approach, increase the data available to answer key scientific and clinical questions, and better inform evidence-based, clinical best practices to enhance the lives of mothers, infants, and children affected by OUD.
PROJECT PURPOSE & GOALS
The purpose of this project is to address the following objectives:
-
Increase diversity of MAT-LINK network through expanded geographic representation and greater representation of racial and ethnic minority populations.
-
Extend follow-up of children from two years to six years of age to assess cognitive and motor development.
-
Improve knowledge about maternal overdose, maternal infection, and infant outcomes, including NAS, and enhance clinical care of pregnant women with OUD and infants with prenatal opioid exposure.